Description
Ozempic Injection (Semaglutide) by Novo Nordisk is a once-weekly injectable GLP-1 receptor agonist used for the management of type 2 diabetes mellitus and cardiovascular risk reduction in adults. It works by mimicking the glucagon-like peptide-1 hormone, stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying, thereby improving blood sugar control and promoting weight loss. Available in doses of 0.25mg (starting dose), 0.5mg, and 1mg via a pre-filled pen device, it is titrated gradually to minimize gastrointestinal side effects. Ozempic has also demonstrated significant cardiovascular benefits, reducing the risk of major adverse cardiac events in patients with established heart disease.
Reviews
There are no reviews yet.